Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory bowel disease: current therapeutic options.

Eugeni Domènech1

  • 1Department of Digestive Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. domenech@ns.hugtip.scs.es

Digestion
|February 25, 2006
PubMed
Summary

This study reviews medical management for inflammatory bowel diseases (IBD), detailing treatments like 5-aminosalicylates, glucocorticoids, and immunomodulators for inducing remission and maintaining long-term control in ulcerative colitis and Crohn's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time trends in strategies for postoperative Crohn's disease management and long-term surgical recurrence: ENEIDA registry data.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Characterization of the stages of chronic liver disease based on plasma proteins involved in systemic inflammation.

Revista espanola de enfermedades digestivas·2026
Same author

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Inflammatory bowel diseases·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry.

Journal of Crohn's & colitis·2026
Same author

Dyshidrotic eczema associated with Upadacitinib use: a paradoxical adverse event or serendipity?

Revista espanola de enfermedades digestivas·2026

Area of Science:

  • Gastroenterology and Internal Medicine
  • Pharmacology and Therapeutics
  • Immunology

Background:

  • Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), require distinct medical management strategies.
  • Treatment focuses on inducing and maintaining remission to improve patient outcomes.
  • Current therapies present challenges related to efficacy, side effects, and cost.

Purpose of the Study:

  • To provide a comprehensive overview of the current medical management strategies for IBD.
  • To delineate the roles of various drug classes in different IBD treatment phases and disease severities.
  • To highlight the indications, benefits, and limitations of key therapeutic agents.

Main Methods:

  • Review of established medical therapies for IBD.

Related Experiment Videos

  • Categorization of treatments based on induction and maintenance phases.
  • Analysis of drug efficacy and safety profiles in UC and CD management.

    • Main Results:

    • 5-Aminosalicylates are primarily for mild active IBD and UC maintenance.
    • Glucocorticoids are mainstays for inducing remission in moderate to severe IBD, despite side effects.
    • Thiopurines are key immunomodulators for steroid-refractory/dependent IBD and long-term maintenance.
    • Cyclosporine and infliximab offer rapid alternatives for refractory UC and CD, respectively.
    • Methotrexate and infliximab are second-line options in CD due to safety and cost.

    Conclusions:

    • A stepwise approach utilizing 5-aminosalicylates, glucocorticoids, and immunomodulators is standard for IBD management.
    • Biologics and other agents provide crucial options for refractory disease.
    • Treatment selection requires balancing efficacy, safety, and economic factors for optimal patient care in IBD.